Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-26
2010-06-29
Fay, Zohreh A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C514S912000
Reexamination Certificate
active
07745461
ABSTRACT:
The topical use of EgLN-3 inhibitors is disclosed for the treatment of dry eye.
REFERENCES:
patent: 4131651 (1978-12-01), Shah et al.
patent: 4370325 (1983-01-01), Packman
patent: 4409205 (1983-10-01), Shively
patent: 4744980 (1988-05-01), Holly
patent: 4818537 (1989-04-01), Guo
patent: 4883658 (1989-11-01), Holly
patent: 4914088 (1990-04-01), Glonek et al.
patent: 4966773 (1990-10-01), Gressel et al.
patent: 5041434 (1991-08-01), Lubkin
patent: 5075104 (1991-12-01), Gressel et al.
patent: 5174988 (1992-12-01), Mautone et al.
patent: 5278151 (1994-01-01), Korb et al.
patent: 5290572 (1994-03-01), MacKeen
patent: 5294607 (1994-03-01), Glonek et al.
patent: 5371108 (1994-12-01), Korb et al.
patent: 5578586 (1996-11-01), Glonek et al.
patent: 5620995 (1997-04-01), Weidmann et al.
patent: 5696166 (1997-12-01), Yanni et al.
patent: 5719164 (1998-02-01), Weidmann et al.
patent: 5800807 (1998-09-01), Hu et al.
patent: 5916898 (1999-06-01), Edwards et al.
patent: 5958912 (1999-09-01), Sullivan
patent: 6020350 (2000-02-01), Weidmann et al.
patent: 6093730 (2000-07-01), Weidmann et al.
patent: 6153607 (2000-11-01), Pflugfelder et al.
patent: 2004/0058875 (2004-03-01), Gamache
patent: 2004/0235082 (2004-11-01), Fourney et al.
patent: 2004/0254215 (2004-12-01), Arend et al.
patent: WO 00/03705 (2000-01-01), None
patent: WO2007/009044 (2007-01-01), None
Ang et al, “Dry eye after refractive surgery,”Current Opinion Ophthalmology, vol. 12, pp. 318-322 (2001).
Coassin et al., “Efficacy of topical nerve growth factor treatment in dogs affected by dry eye,”Graefe's Archives Clinical Experimental Ophthalmology, vol. 243, pp. 151-155 (2005).
Esquenazi et al., “Topical Combination of NGF and DHA Increases Rabbit Corneal Nerve Regeneration after Photorefractive Keratectomy,”Investivative Opthalmology Visual Science, vol. 46(9), pp. 3121-3127 (2005).
Ivan et al., “Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor,”PNAS, vol. 99(21), pp. 13459-13464 (2002).
Joo et al., The Effect of Nerve Growth Factor on Corneal Sensitivity After Laser in Situ Keratomileusis,Arch Ophthalmology, vol. 122, pp. 1338-1341 (2004).
Lee et al., “Neuronal apoptosis linked to EgIN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer,”Cancer Cell, vol. 8, pp. 155-167 (2005).
Lemp et al., “Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes,”CLAO Journal, vol. 21(4), pp. 221-231 (1995).
Li et al., “JNK and ERK MAP kinases mediate induction of IL-1β, TNF-α and IL-8 following hyperosmolar stress in human limbal epithelial cells,”Experimental Eye Research, vol. 82, pp. 588-596 (2006).
Lipscomb et al., “Expression of the SM-20 Gene Promotes Death in Nerve Growth Factor-Dependent Sympathetic Neurons,”J. Neurochemistry, vol. 73(1), pp. 429-432 (1999).
Lipscomb et al., “SM-20 Is a Novel Mitochondrial Protein That Causes Caspase-dependent Cell Death in Nerve Growth Factor-dependent Neurons,”The Journal of Biological Chemistry, vol. 276 (7), pp. 5085-5092 (2001).
Marsh et al., Topical Nonpreserved Methylprednisolone Therapy for Keratoconjunctivitis Sicca in Sjögren Syndrome,Ophthalmology, vol. 106, pp. 811-816 (1999).
McCulley et al., “Tear Film Structure and Dry Eye,”Contactologia, vol. 20, pp. 145-149 (1998).
Pepose et al., “Is There a Role for Neurotrophin Treatment of the Ocular Surface Following Laser in Situ Keratomileusis (LASIK)?,”American Joournal of Ophthalmology, vol. 139 (6), pp. 1090-1094 (2005).
Peso et al., “The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen,”The Journal of Biological Chemistry, vol. 278(49), pp. 4869048695 (2003).
Schlingensiepen et al., “The Role of Jun Transcription Factor Expression and Phosphorylation in Neuronal Differentiation, Neuronal Cell Death, and Plastic Adaptations in Vivo,”Cell Molecular Neurobiology, vol. 14(5), pp. 487-505 (1994).
Shine et al., Keratoconjunctivitis Sicca Associated with Meibomian Secretion Polar Lipid Abnormality,Archives of Ophthalmology, vol. 116, pp. 849-852 (1998).
Song et al., “Neurturin-Deficient Mice Develop Dry Eye and Keratoconjunctivitis Sicca,”Investivative Ophthalmology&Visual Science, vol. 44(10), pp. 4223-4229 (2003).
Straub et al., “Induction of SM-20 in PC12 cells leads to increased cytochrome c levels, accumulation of cytochrome c in the cytosol, and caspase-dependent cell death,”J. Neurochemistry, vol. 85(2), pp. 318-328 (2003).
Tauber et al.,Lacrimal Gland, Tear Film and Dry Eye Syndromes 2, Plenum Press, New York (1998), “A Dose-Ranging Clinical Trial to Assess the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients with Keratoconjunctivitis Sicca,” pp. 969-972.
Zhang et al., Altered Corneal Nerves in Aqueous Tear Deficiency Viewed by in Vivo Confocal Microscopy,Cornea, vol. 24(7), pp. 818-824 (2005).
Zoukhri et al., “c-Jun HN2-terminal kinase mediates interleukin-1β-induced inhibition of lacrinal gland secretion,”Journal of Neurochemistry, vol. 96(1), pp. 126-135 (2006).
Alcon Research, Ltd.
Fay Zohreh A
Ryan Patrick M.
LandOfFree
Method of treating dry eye disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating dry eye disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating dry eye disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4185010